Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB)

Autor(es)

Barros, Caio H. N. ^{[1, 2]} ; Fulaz, Stephanie ^{[1, 2]} ; Stanisic, Danijela ^[1] ; Tasic, Ljubica ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Inst Chem, Biol Chem Lab, BR-13083970 Campinas, SP - Brazil

^[2] Univ Coll Dublin, Sch Bioproc & Chem Engn, Dublin D04 V1W8 - Ireland

• Tipo de documento: Artigo de Revisão
• Fonte: ANTIBIOTICS-BASEL; v. 7, n. 3 SEP 2018.
• Citações Web of Science: 11

Resumo

Multidrug-resistant bacteria (MDRB) are extremely dangerous and bring a serious threat to health care systems as they can survive an attack from almost any drug. The bacteria's adaptive way of living with the use of antimicrobials and antibiotics caused them to modify and prevail in hostile conditions by creating resistance to known antibiotics or their combinations. The emergence of nanomaterials as new antimicrobials introduces a new paradigm for antibiotic use in various fields. For example, silver nanoparticles (AgNPs) are the oldest nanomaterial used for bactericide and bacteriostatic purposes. However, for just a few decades these have been produced in a biogenic or bio-based fashion. This review brings the latest reports on biogenic AgNPs in the combat against MDRB. Some antimicrobial mechanisms and possible silver resistance traits acquired by bacteria are also presented. Hopefully, novel AgNPs-containing products might be designed against MDR bacterial infections. (AU)

• Processo FAPESP: 15/12534-5 - Estudo das interações supramoleculares em nanopartículas de prata e sua atividade antimicrobiana
• Beneficiário: Caio Henrique Nasi de Barros
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 14/50867-3 - INCT 2014: Instituto Nacional de Ciência e Tecnologia de Bioanalítica
• Beneficiário: Marco Aurelio Zezzi Arruda
• Modalidade de apoio: Auxílio à Pesquisa - Temático